Knowledge and attitude about Pharmacovigilance practices of pharmacy professionals of community pharmacy and hospital pharmacy in Spain
e202007068
Keywords:
Pharmacovigilance, Survey, Knowledge, Training, Attitude, Skills, Obligations, Pharmaceutical Professionals, Adverse drug reactionsAbstract
Background: The justification of the study was to assess the degree of knowledge of Spanish pharmacists in the field of Pharmacovigilance, their degree of notification of adverse drug reactions and their need for training, establishing the differences between community pharmacy pharmacist and those of hospital pharmacy.
Methods: A questionnaire with twelve questions on Pharmacovigilance was designed. The distribution and collection of the questionnaires were carried out via online in collaboration with the Official Colleges of Pharmacists and the Spanish Society of Hospital Pharmacy during the period from November 2018 to June 2019. The target population were the pharmacists registered or belonging to the Spanish Society of Hospital Pharmacy. The results were processed using a descriptive and analytical analysis. The qualitative variables were presented with their frequency distribution and the quantitative with their mean and standard deviation.
Results: 99% of hospital pharmacists said they had evidence of suspected adverse reactions and 96.9% of them ever reported. 73.5% of community pharmacists stated that they had knowledge of suspected adverse reactions but only 48.7% confirmed that they notified them. In general, the pharmacists surveyed agreed on the importance of Pharmacovigilance and believed that the quality of treatments could be improved and the Spanish health system would be saved if Pharmacovigilance was applied more.
Conclusions: Our results indicated that hospital pharmacists report much more adverse drug reactions than community pharmacist does. It also hospital pharmacists who know best the obligations they have with Pharmacovigilance. The surveyed pharmacists thought that the development of actions in Pharmacovigilance would increase the adherence of pharmaceutical professionals to the notification and would imply improvements in the quality of treatments, the rational use of medications and patient safety.
Key words: Pharmacovigilance, Survey, Knowledge, Training, Attitude, Skills, Obligations, Pharmaceutical, Professionals, Adverse drug reactions.
Downloads
References
Real Decreto 577/2013, de 26 de julio, por el que se regula la farmacovigilancia de medicamentos de uso humano. Ministerio de Sanidad, Servicios Sociales e Igualdad. BOE-A-2013-8191. [Disponible en la web: https://www.boe.es/diario_boe/txt.php?id=BOE-A-2013-8191.
Alomar M, Palaian S, Al-tabakha MM. Pharmacovigilance in perspective: drug withdrawals, data mining and policy implications. F1000Res. 2019 Dec 16;8:2109 [Disponible en la web: https://f1000research.com/articles/8-2109].
Elshafie S, Zaghloul I, Roberti A. Pharmacovigilance in developing countries (part I): importance and challenges.. Int J Clin Pharm. 2018 Aug;40(4):758-763.
World Health Organization. International drug monitoring: the role of nacional centres. Tecnical Report Series Nº 498. Geneva: WHO, 1972.
Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. Art. 1 (11).
Su C, Ji H, Su Y. Hospital pharmacists´ knowledge and opinions regarding adverse drug reaction reporting in Northern China. Pharmacoepidemiol Drug Saf. 2010; 19(3): 217-222.
Moinuddin K, Ali S, Al-Aqqad AQ, Salem SO, Al-Dossari MA, Ananzeh AM, Baqar JB. Knowledge and Attitude of Health-Care Professionals Toward Adverse Drug Reactions Reporting at King Saud Medical City. J Pharm Bioallied Sci. 2018 Jan-Mar;10(1):29-34.
Oreagba IA, Ogunleye OJ, Olayemi SO. The Knowledge, perceptions and practice of pharmacovigilance amongst comunity pharmacists in Lagos state, south west Nigeria. Pharmacoepidemiol Drug Saf. 2011; 20(1): 30-5.
Vessal G, Mardani Z, Mollai M. Knowledge, attitudes, and perceptions of pharmacists to adverse drug reaction reporting in Iran. Pharm World Sci. 2009; 31(2): 183-7.
Tarragó Portelles SS, Gravier Hrnandez R, Gil del Valle L. La Farmacovigilancia en Cuba y la Infranotificaciones de Reacciones Adversas a los Medicamentos. Horizonte Sanitario. ISSN 1665-3262, Vol. 18, Nº. 1, 2019, págs.7-15.
Beijer Hl, Blaey CJ. Hospitalizations caused by adverse drug reactions (ADR): A meta-analysis of observational studies. Pharm World Sci 2002; 24: 46-54.
Phansalkar S, Hoffman JM, Nebeker JR, Hurdle JF. Pharmacists versus nonpharmacists in adverse drug event detection: a metaanalysis and systematic review. Am J Health Syst Pharm. 2007; 64(8): 842-849.
Shamim S, Sharib SM, Malhi SM, Muntaha S, Raza H, Ata S et al. Adverse drug reactions (ADRS) reporting: awareness and reasons of under-reporting among health care professionals, a challenge for pharmacists. SpringerPlus. 2016; 5(1).
Zolezzi M, Parsotam N. Adverse drug reaction reporting in New Zealand: implications for pharmacists. Ther Clin Risk Manag. 2005; 1 (3): 181-8.
Van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf. 2004; 13 (7): 457-64.
Herdeiro MT, Figueiras A, Polónia J, Gestal-Otero JJ. Influence of pharmacists attitudes on adverse drug reaction reporting: a case control study in Portugal. Drug Saf. 2006; 29(4): 331-40.
Centro Andaluz de Farmacovigilancia. Notificación por profesionales sanitarios 2011. Disponible en: http//si.easp.es/csalud/cafv2011/profesionales sanitarios.html.
Servei Andorrá D’atenció Sanitária. Hospital Nostra Senyora de Meritxell. Memoria 2017. www.saas.ad.
Tena T, Rivera A, Beas AI, Alonso C, Rodríguez R, Bravo E. Farmacovigilancia: ¿Y si notificamos? Farmacéuticos Comunitarios. 2014 Jun 01; 6 (2): 48-52. doi:10.5672/FC.2173-9218. (2014/Vol6).002.07. [Disponible en la web: https://www.raco.cat/index.php/FC/article/view/321038/411523].
Acuña Ferradanes A, González Añón D, Castillo Páramo A, Fornos Pérez JA, Andrés Iglesias JC, Andrés Rodríguez NF. Metodología para evaluar las actitudes y aptitudes sobre Farmacovigilancia en los farmacéuticos comunitarios. Aplicación en la provincia de Pontevedra. Pharm Care Esp 2012; 14(3):110-121.
Green CF, Mottram DR, Rowe PH, Pirmohamed M. Attitudes and knowledge of hospital pharmacists to adverse drug reaction reporting. Br J Clin Pharmacol. 2001; 51(1): 81-86.
Subish P, Mohamend I, Ibrahim, Pranaya M. Health professionals´knowledge, attitude and practices towards pharmacovigilance in Nepal. Pharm Pract (Granada). 2011;9 (4): 228-235.
Li R, Curtain C, Bereznicki L, Zaidi STR. Community pharmacists´ knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. Int J Clin Pharm. 2018; 40(4): 878-889.
Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of Under Reporting of Adverse Drug Reactions: a Systematic Review. Drug Saf 2009; 32(1): 19-31.
Varallo F, Paim Guimaräes S, Rodriguez Abjaude S, de Carvalho Mastroianni P. Causes for the underreporting of adverse drug events by health professionals: a systematic review. Rev Esc Enferm USP. 2014; 48(4): 739-47.
Alkhalidi D, Jamshed SQ, Elkalmi RM, Baig MR, Aslam A, Hassali MA. Opinions of the public, attitudes and experiences towards drug safety in Dubai, United Arab Emirates: a qualitative approach. Pharmacy (Basel). 2019; 7(1). Pii: E19.
García A, García-García P, Marcos N et al. Conocimientos en farmacovigilancia en los estudios bio-sanitarios: resultados preliminares. VII Jornadas de Farmacovigilancia. Murcia, 2008. El panorama actual de la farmacovigilancia.
Reumerman M, Tichelaar J, Piersma B, Richir MC, van Agtmael MA. Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature. Eur J Clin Pharmacol. 2018; 74(10): 1235-1248.
Pérez O, Aguilar MA. Nivel de información sobre Farmacovigilancia en los estudiantes de las carreras de Medicina y de Farmacia de la Universidad Central de Venezuela en el año 2011. Rev. Inst. Nac. Hig. “Rafael Rangel”. 2014; 45819. 80-91.
Pagotto C, Varallo F, Mastroianni P. Impact of educational interventions on adverse drug events reporting. International Journal of Technology Assessment In Health Care. 2013; 29 (4): 410-417.
Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, Montastruc JL, Bagheri H. Improving adverse drug reaction reporting in hospitals: results of the French Pharmacovigilance in Midi-Pyrénées región (PharmacoMIP) network 2-year pilot study. Drug Saf. 2010; 33(5): 409-16.
Downloads
Published
How to Cite
License
Copyright (c) 2020 Rafael Lozano Fernández, Ernesto Vera Sánchez, Mª del Carmen Lozano Estevan, Mariano Madurga Sanz, Ana Serna Núñez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Usted es libre de:
Compartir — copiar y redistribuir el material en cualquier medio o formato.
La licenciante no puede revocar estas libertades en tanto usted siga los términos de la licencia.
Bajo los siguientes términos:
Atribución — Usted debe dar crédito de manera adecuada , brindar un enlace a la licencia, e indicar si se han realizado cambios. Puede hacerlo en cualquier forma razonable, pero no de forma tal que sugiera que usted o su uso tienen el apoyo de la licenciante.
NoComercial — Usted no puede hacer uso del material con propósitos comerciales.
SinDerivadas — Si remezcla, transforma o crea a partir del material, no podrá distribuir el material modificado.
No hay restricciones adicionales — No puede aplicar términos legales ni medidas tecnológicas que restrinjan legalmente a otras a hacer cualquier uso permitido por la licencia.
Avisos:
No tiene que cumplir con la licencia para elementos del material en el dominio público o cuando su uso esté permitido por una excepción o limitación aplicable.
No se dan garantías. La licencia podría no darle todos los permisos que necesita para el uso que tenga previsto. Por ejemplo, otros derechos como publicidad, privacidad, o derechos morales pueden limitar la forma en que utilice el material.
![¿Cómo evaluar para la RESP? [PARA REVISORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-revisores-0eaa113abcbc4fc554c7c6c7840ca4c6.jpg)
![¿Cómo recibir avisos sobre nuevos artículos de la RESP? [PARA LECTORES]](https://ojs.sanidad.gob.es/public/site/images/rmartinb/pastilla-lectores-aa689338e95aab07df45b4b0d583188f.jpg)
